These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 33112824)

  • 1. Kinome rewiring during acquired drug resistance in neuroendocrine neoplasms.
    Gérard C; Lagarde M; Poizat F; Oziel-Taieb S; Garcia V; Roche C; Niccoli P; Barlier A; Romano D
    Endocr Relat Cancer; 2021 Jan; 28(1):39-51. PubMed ID: 33112824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors.
    Vandamme T; Beyens M; de Beeck KO; Dogan F; van Koetsveld PM; Pauwels P; Mortier G; Vangestel C; de Herder W; Van Camp G; Peeters M; Hofland LJ
    Br J Cancer; 2016 Mar; 114(6):650-8. PubMed ID: 26978006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MYC Upregulation Confers Resistance to Everolimus and Establishes Vulnerability to Cyclin-Dependent Kinase Inhibitors in Pancreatic Neuroendocrine Neoplasm Cells.
    Terracciano F; Capone A; Montori A; Rinzivillo M; Partelli S; Panzuto F; Pilozzi E; Arcidiacono PG; Sette C; Capurso G
    Neuroendocrinology; 2021; 111(8):739-751. PubMed ID: 32615570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relevance of neuroendocrine tumours models assessed by kinomic profiling.
    Romano D
    Ann Endocrinol (Paris); 2019 Jun; 80(3):144-148. PubMed ID: 31054767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
    Zanini S; Renzi S; Giovinazzo F; Bermano G
    Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro.
    Aristizabal Prada ET; Nölting S; Spoettl G; Maurer J; Auernhammer CJ
    Neuroendocrinology; 2018; 106(1):58-73. PubMed ID: 28226315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.
    Nölting S; Rentsch J; Freitag H; Detjen K; Briest F; Möbs M; Weissmann V; Siegmund B; Auernhammer CJ; Aristizabal Prada ET; Lauseker M; Grossman A; Exner S; Fischer C; Grötzinger C; Schrader J; Grabowski P;
    PLoS One; 2017; 12(8):e0182852. PubMed ID: 28800359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic Profiles and Current Therapeutic Agents in Neuroendocrine Neoplasms.
    Ohmoto A; Morizane C
    Curr Drug Targets; 2020; 21(4):389-405. PubMed ID: 31633473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease.
    Freitag H; Christen F; Lewens F; Grass I; Briest F; Iwaszkiewicz S; Siegmund B; Grabowski P
    Neuroendocrinology; 2017; 105(1):90-104. PubMed ID: 27513674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical drug studies in MEN1-related neuroendocrine neoplasms (MEN1-NENs).
    Grozinsky-Glasberg S; Lines KE; Avniel-Polak S; Bountra C; Thakker RV
    Endocr Relat Cancer; 2020 Sep; 27(9):R345-R355. PubMed ID: 32590358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
    François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook.
    Mateo J; Heymach JV; Zurita AJ
    Mol Diagn Ther; 2012 Jun; 16(3):151-61. PubMed ID: 22515658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic treatment of neuroendocrine tumors with hepatic metastases.
    Demirkan BH; Eriksson B
    Turk J Gastroenterol; 2012; 23(5):427-37. PubMed ID: 23161287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.
    Tijeras-Raballand A; Neuzillet C; Couvelard A; Serova M; de Gramont A; Hammel P; Raymond E; Faivre S
    Target Oncol; 2012 Sep; 7(3):173-81. PubMed ID: 22923165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours.
    Fazio N; Buzzoni R; Baudin E; Antonuzzo L; Hubner RA; Lahner H; DE Herder WW; Raderer M; Teulé A; Capdevila J; Libutti SK; Kulke MH; Shah M; Dey D; Turri S; Aimone P; Massacesi C; Verslype C
    Anticancer Res; 2016 Feb; 36(2):713-9. PubMed ID: 26851029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus and pancreatic neuroendocrine tumors (PNETs): Activity, resistance and how to overcome it.
    Capozzi M; Caterina I; De Divitiis C; von Arx C; Maiolino P; Tatangelo F; Cavalcanti E; Di Girolamo E; Iaffaioli RV; Scala S; Tafuto S;
    Int J Surg; 2015 Sep; 21 Suppl 1():S89-94. PubMed ID: 26123382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroendocrine neoplasms of the GI tract: the role of cytotoxic chemotherapy.
    Khasraw M; Yap SY; Ananda S
    Expert Rev Anticancer Ther; 2013 Apr; 13(4):451-9. PubMed ID: 23560839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.
    Gagliano T; Bellio M; Gentilin E; Molè D; Tagliati F; Schiavon M; Cavallesco NG; Andriolo LG; Ambrosio MR; Rea F; Degli Uberti E; Zatelli MC
    Endocr Relat Cancer; 2013 Aug; 20(4):463-75. PubMed ID: 23653462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of Peroxiredoxin-2 in Well-Differentiated Pancreatic Neuroendocrine Tumors and Its Utility as a Biomarker for Predicting the Response to Everolimus.
    Kim EJ; Kim YJ; Lee HI; Jeong SH; Nam HJ; Cho JH
    Antioxidants (Basel); 2020 Nov; 9(11):. PubMed ID: 33182509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms.
    Grillo F; Florio T; Ferraù F; Kara E; Fanciulli G; Faggiano A; Colao A;
    Endocr Relat Cancer; 2018 Sep; 25(9):R453-R466. PubMed ID: 29769293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.